Last reviewed · How we verify
Placebo - Concentrate
Placebo - Concentrate is a Small molecule drug developed by University of Southern California. It is currently FDA-approved for Clinical trial control for various conditions. Also known as: placebo, placebos, sugar water, physiologic saline solution.
Placebo produces therapeutic effects through patient expectation and the psychobiological placebo response, without active pharmacological ingredients.
Placebo is a treatment used in clinical trials for various conditions, including Parkinson's disease, pain, postoperative care, cognitive decline, and Systemic Lupus Erythematosus (SLE). It is also used as a control intervention in studies comparing it to other treatments, such as Lu AF82422 and Bupivacaine Hydrochloride, in spinal administration.
At a glance
| Generic name | Placebo - Concentrate |
|---|---|
| Also known as | placebo, placebos, sugar water, physiologic saline solution |
| Sponsor | University of Southern California |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebo works via psychological and neurobiological mechanisms including expectation, conditioning, and activation of endogenous pain-relief and reward pathways. The placebo effect is a real physiological phenomenon mediated by the brain's response to the therapeutic context, rather than by direct drug action on molecular targets. It is commonly used as a control in clinical trials and has documented efficacy in conditions involving subjective symptoms such as pain, nausea, and fatigue.
Approved indications
- Clinical trial control for various conditions
Common side effects
- Nocebo effects (negative expectancy-driven symptoms)
Key clinical trials
- The Impact of OliPhenolia® Supplementation on Exercise Induced Inflammation and Functional Movement in Humans. (NA)
- A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE) (PHASE3)
- A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (PHASE3)
- Heart & Health Study (NA)
- Whey Protein Supplementation and Serum Mineral Status in Elite Endurance and Power Athletes (NA)
- Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis (PHASE1)
- A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia (PHASE3)
- IncobotulinumtoxinA (Xeomin) to Treat Focal Hand Dystonia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo - Concentrate CI brief — competitive landscape report
- Placebo - Concentrate updates RSS · CI watch RSS
- University of Southern California portfolio CI
Frequently asked questions about Placebo - Concentrate
What is Placebo - Concentrate?
How does Placebo - Concentrate work?
What is Placebo - Concentrate used for?
Who makes Placebo - Concentrate?
Is Placebo - Concentrate also known as anything else?
What development phase is Placebo - Concentrate in?
What are the side effects of Placebo - Concentrate?
Related
- Manufacturer: University of Southern California — full pipeline
- Indication: Drugs for Clinical trial control for various conditions
- Also known as: placebo, placebos, sugar water, physiologic saline solution
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing